Günter Steiner

Summary

Affiliation: Medical University of Vienna
Country: Austria

Publications

  1. ncbi request reprint Auto-antibodies and autoreactive T-cells in rheumatoid arthritis: pathogenetic players and diagnostic tools
    Günter Steiner
    Department of Rheumatology, Internal Medicine III, Medical University of Vienna, Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna and Ludwig Boltzmann Institute for Rheumatology, Vienna, Austria
    Clin Rev Allergy Immunol 32:23-36. 2007
  2. ncbi request reprint Aberrant expression of the autoantigen heterogeneous nuclear ribonucleoprotein-A2 (RA33) and spontaneous formation of rheumatoid arthritis-associated anti-RA33 autoantibodies in TNF-alpha transgenic mice
    Silvia Hayer
    Department of Rheumatology, Internal Medicine III, Medical University of Vienna, Vienna, Austria
    J Immunol 175:8327-36. 2005
  3. pmc JNK1 is not essential for TNF-mediated joint disease
    Marcus Koller
    Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Austria
    Arthritis Res Ther 7:R166-73. 2005
  4. pmc Endothelial progenitor cells in active rheumatoid arthritis: effects of tumour necrosis factor and glucocorticoid therapy
    Johannes Grisar
    Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    Ann Rheum Dis 66:1284-8. 2007
  5. doi request reprint Immunodominant T-cell epitopes of hnRNP-A2 associated with disease activity in patients with rheumatoid arthritis
    Sylvie Trembleau
    Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria
    Eur J Immunol 40:1795-808. 2010
  6. ncbi request reprint The rheumatoid arthritis-associated autoantigen hnRNP-A2 (RA33) is a major stimulator of autoimmunity in rats with pristane-induced arthritis
    Markus H Hoffmann
    Department of Rheumatology, Medical University of Vienna, Vienna, Austria
    J Immunol 179:7568-76. 2007
  7. ncbi request reprint Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction
    Jochen Zwerina
    University of Vienna, Vienna, Austria
    Arthritis Rheum 50:277-90. 2004
  8. ncbi request reprint Phenotypic and functional deficiencies of monocyte-derived dendritic cells in systemic lupus erythematosus (SLE) patients
    Marcus Koller
    Department of Rheumatology, Internal Medicine III, Medical University of Vienna, General Hospital of Vienna, Währingergürtel 18 20, A 1090 Vienna, Austria
    Int Immunol 16:1595-604. 2004
  9. pmc The spliceosomal autoantigen heterogeneous nuclear ribonucleoprotein A2 (hnRNP-A2) is a major T cell autoantigen in patients with systemic lupus erythematosus
    Ruth Fritsch-Stork
    Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Austria
    Arthritis Res Ther 8:R118. 2006
  10. doi request reprint Cell death and cytokine production induced by autoimmunogenic hydrocarbon oils
    Sonja Herman
    Division of Rheumatology, Medical University of Vienna, Vienna, Austria
    Autoimmunity 45:602-11. 2012

Collaborators

Detail Information

Publications33

  1. ncbi request reprint Auto-antibodies and autoreactive T-cells in rheumatoid arthritis: pathogenetic players and diagnostic tools
    Günter Steiner
    Department of Rheumatology, Internal Medicine III, Medical University of Vienna, Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna and Ludwig Boltzmann Institute for Rheumatology, Vienna, Austria
    Clin Rev Allergy Immunol 32:23-36. 2007
    ..This has made possible the development of novel therapeutic concepts that may allow to treat the disease more effectively in its early stages where the chances are highest to interrupt the deleterious processes...
  2. ncbi request reprint Aberrant expression of the autoantigen heterogeneous nuclear ribonucleoprotein-A2 (RA33) and spontaneous formation of rheumatoid arthritis-associated anti-RA33 autoantibodies in TNF-alpha transgenic mice
    Silvia Hayer
    Department of Rheumatology, Internal Medicine III, Medical University of Vienna, Vienna, Austria
    J Immunol 175:8327-36. 2005
    ..These findings suggest that overproduction of TNF-alpha leads to aberrant expression of hnRNP-A2 in the rheumatoid joint and subsequently to autoimmune reactions, which may enhance the inflammatory and destructive process...
  3. pmc JNK1 is not essential for TNF-mediated joint disease
    Marcus Koller
    Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Austria
    Arthritis Res Ther 7:R166-73. 2005
    ..Thus, JNK1 activation does not seem to be essential for TNF-mediated arthritis...
  4. pmc Endothelial progenitor cells in active rheumatoid arthritis: effects of tumour necrosis factor and glucocorticoid therapy
    Johannes Grisar
    Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    Ann Rheum Dis 66:1284-8. 2007
    ....
  5. doi request reprint Immunodominant T-cell epitopes of hnRNP-A2 associated with disease activity in patients with rheumatoid arthritis
    Sylvie Trembleau
    Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria
    Eur J Immunol 40:1795-808. 2010
    ..These data suggest involvement of hnRNP-A2 specific cellular autoimmune responses in RA pathogenesis...
  6. ncbi request reprint The rheumatoid arthritis-associated autoantigen hnRNP-A2 (RA33) is a major stimulator of autoimmunity in rats with pristane-induced arthritis
    Markus H Hoffmann
    Department of Rheumatology, Medical University of Vienna, Vienna, Austria
    J Immunol 179:7568-76. 2007
    ..Taken together, these data suggest hnRNP-A2 to be among the primary inducers of autoimmunity in PIA. Therefore, this Ag might play a pivotal role in the pathogenesis of PIA and possibly also human RA...
  7. ncbi request reprint Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction
    Jochen Zwerina
    University of Vienna, Vienna, Austria
    Arthritis Rheum 50:277-90. 2004
    ..To investigate the efficacy of single and combined blockade of tumor necrosis factor (TNF), interleukin-1 (IL-1), and RANKL pathways on synovial inflammation, bone erosion, and cartilage destruction in a TNF-driven arthritis model...
  8. ncbi request reprint Phenotypic and functional deficiencies of monocyte-derived dendritic cells in systemic lupus erythematosus (SLE) patients
    Marcus Koller
    Department of Rheumatology, Internal Medicine III, Medical University of Vienna, General Hospital of Vienna, Währingergürtel 18 20, A 1090 Vienna, Austria
    Int Immunol 16:1595-604. 2004
    ..Our data imply a crucial role of APC in the immunological imbalance in SLE for foreign and self-antigen reactivity...
  9. pmc The spliceosomal autoantigen heterogeneous nuclear ribonucleoprotein A2 (hnRNP-A2) is a major T cell autoantigen in patients with systemic lupus erythematosus
    Ruth Fritsch-Stork
    Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Austria
    Arthritis Res Ther 8:R118. 2006
    ..Taken together, the pronounced peripheral T cell reactivity to hnRNP-A2 observed in the majority of SLE patients and the distinct phenotype of patient-derived CD8+ TCCs suggest a role for these T cells in the pathogenesis of SLE...
  10. doi request reprint Cell death and cytokine production induced by autoimmunogenic hydrocarbon oils
    Sonja Herman
    Division of Rheumatology, Medical University of Vienna, Vienna, Austria
    Autoimmunity 45:602-11. 2012
    ..The higher serum IL-1β levels in pristane-injected animals might be caused by both inflammasome-dependent and -independent mechanisms, such as passive release from dying-cells and probably extracellular maturation of pro-IL-1β...
  11. ncbi request reprint Pro-inflammatory cytokines in rheumatoid arthritis: pathogenetic and therapeutic aspects
    Josef S Smolen
    Division of Rheumatology, Internal Medicine III, Medical University of Vienna, Austria
    Clin Rev Allergy Immunol 28:239-48. 2005
    ....
  12. pmc CD44 is a determinant of inflammatory bone loss
    Silvia Hayer
    Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, A 1090 Vienna, Austria
    J Exp Med 201:903-14. 2005
    ..These data identify CD44 as a critical inhibitor of TNF-driven joint destruction and inflammatory bone loss...
  13. ncbi request reprint Effects of short-term infliximab therapy on autoantibodies in systemic lupus erythematosus
    Martin Aringer
    Medical University of Vienna, Vienna, Austria
    Arthritis Rheum 56:274-9. 2007
    ..To analyze changes in autoantibodies occurring in patients with systemic lupus erythematosus (SLE) treated with 4 infusions of the chimeric anti-tumor necrosis factor alpha (TNFalpha) antibody infliximab...
  14. ncbi request reprint Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study
    Martin Aringer
    Internal Medicine III, Medical University of Vienna, Vienna, Austria
    Arthritis Rheum 50:3161-9. 2004
    ....
  15. ncbi request reprint Arthritis induces lymphocytic bone marrow inflammation and endosteal bone formation
    Birgit Görtz
    Division of Rheumatology, Department of Internal Medicine III, University of Vienna, Vienna, Austria
    J Bone Miner Res 19:990-8. 2004
    ..Bone marrow next to arthritic lesions exhibits B-lymphocyte-rich infiltrates, which express BMPs and stimulate endosteal bone formation. Thus, bone marrow actively participates in the arthritic process...
  16. pmc The need for prognosticators in rheumatoid arthritis. Biological and clinical markers: where are we now?
    Josef S Smolen
    Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    Arthritis Res Ther 10:208. 2008
    ..The analysis suggests the search for better markers to predict outcomes and therapeutic responsiveness in rheumatoid arthritis needs to be intensified...
  17. pmc Epidermal loss of JunB leads to a SLE phenotype due to hyper IL-6 signaling
    Pamina Pflegerl
    Institute of Clinical Pathology, Department of Internal Medicine III, Medical University of Vienna, Währingergürtel 18 20, A 1090 Vienna, Austria
    Proc Natl Acad Sci U S A 106:20423-8. 2009
    ..Thus, keratinocyte-induced IL-6 secretion can cause SLE and systemic autoimmunity. Our results support trials to use alpha-IL-6 receptor antibody therapy for treatment of SLE...
  18. doi request reprint Activation of the interferon-gamma signaling pathway in systemic lupus erythematosus peripheral blood mononuclear cells
    Thomas Karonitsch
    Department of Rheumatology, Internal Medicine III, Medical University of Vienna, Vienna, Austria
    Arthritis Rheum 60:1463-71. 2009
    ....
  19. pmc Repair of local bone erosions and reversal of systemic bone loss upon therapy with anti-tumor necrosis factor in combination with osteoprotegerin or parathyroid hormone in tumor necrosis factor-mediated arthritis
    Kurt Redlich
    Department of Internal Medicine III, University of Vienna, Vienna, Austria
    Am J Pathol 164:543-55. 2004
    ....
  20. doi request reprint Interferon signals and monocytic sensitization of the interferon-γ signaling pathway in the peripheral blood of patients with rheumatoid arthritis
    Thomas Karonitsch
    Division of Rheumatology, Internal Medicine III, Medical University of Vienna, Vienna, Austria
    Arthritis Rheum 64:400-8. 2012
    ..The aim of this study was to determine the systemic activity of the IFN/STAT-1 signaling pathway in the peripheral blood cells of patients with RA...
  21. ncbi request reprint Does mixed connective tissue disease exist? Yes
    Martin Aringer
    Department of Rheumatology, Internal Medicine III, Medical University of Vienna, AKH, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    Rheum Dis Clin North Am 31:411-20, v. 2005
    ..The authors believe that the concept is useful in daily practice and accurate in the idea that MCTD constitutes a disease entity of its own...
  22. pmc Gait changes precede overt arthritis and strongly correlate with symptoms and histopathological events in pristane-induced arthritis
    Markus H Hoffmann
    Division of Rheumatology, Internal Medicine III, Medical University of Vienna, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    Arthritis Res Ther 12:R41. 2010
    ..To investigate this issue a detailed analysis of the pathologic changes occurring during the prodromal and early stages of PIA was performed...
  23. ncbi request reprint Osteoprotegerin protects against generalized bone loss in tumor necrosis factor-transgenic mice
    Georg Schett
    Department of Internal Medicine III, Division of Rheumatology, University of Vienna, Wahringer Gurtel 18 20, A 1090 Vienna, Austria
    Arthritis Rheum 48:2042-51. 2003
    ..To investigate the role of tumor necrosis factor (TNF) in systemic bone loss of chronic inflammatory conditions, such as rheumatoid arthritis (RA), and to address the therapeutic potential of osteoclast blockade...
  24. doi request reprint Nucleic acid-associated autoantigens: pathogenic involvement and therapeutic potential
    Markus H Hoffmann
    Division of Rheumatology, Internal Medicine III, Medical University of Vienna, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    J Autoimmun 34:J178-206. 2010
    ..Furthermore, recent advances in immunotherapy such as antigen-specific approaches targeted at nucleic acid-binding antigens are discussed...
  25. ncbi request reprint Tumor necrosis factor alpha-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin
    Kurt Redlich
    University of Vienna, Vienna, Austria
    Arthritis Rheum 46:785-92. 2002
    ..To study the effects of osteoclast-targeted therapies, such as osteoprotegerin (OPG) and pamidronate, on joint inflammation and bone destruction using a tumor necrosis factor alpha (TNF alpha)-transgenic mouse model...
  26. pmc Osteoclasts are essential for TNF-alpha-mediated joint destruction
    Kurt Redlich
    Department of Internal Medicine III, Division of Rheumatology, University of Vienna, Vienna, Austria
    J Clin Invest 110:1419-27. 2002
    ..Therefore, in addition to the use of anti-inflammatory therapies, osteoclast inhibition could be beneficial for the treatment of rheumatoid arthritis...
  27. ncbi request reprint Expression patterns of CD44 and CD44 splice variants in patients with rheumatoid arthritis
    J Grisar
    Divison of Rheumatology, Department of Internal Medicine III, Medical University Vienna, Vienna, Austria
    Clin Exp Rheumatol 30:64-72. 2012
    ..We therefore studied the expression of various CD44 splicevariants in the circulation and synovial tissue of patients with RA and correlated expression with clinical features...
  28. ncbi request reprint Depletion of endothelial progenitor cells in the peripheral blood of patients with rheumatoid arthritis
    Johannes Grisar
    Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    Circulation 111:204-11. 2005
    ..Because the quantity of endothelial progenitor cells (EPCs) in the peripheral blood is correlated inversely with cardiovascular risk, we studied whether such abnormalities could also be observed in patients with RA...
  29. pmc RNA chaperone activity of protein components of human Ro RNPs
    Aurélia Belisova
    Department of Medical Biochemistry, Medical University of Vienna, Vienna Biocenter, Dr Bohrgasse 9, A 1030 Vienna, Austria
    RNA 11:1084-94. 2005
    ....
  30. ncbi request reprint Therapeutic strategies for rheumatoid arthritis
    Josef S Smolen
    Division of Rheumatology, Department of Internal Medicine III, University of Vienna, Austria
    Nat Rev Drug Discov 2:473-88. 2003
    ....
  31. ncbi request reprint Rheumatoid arthritis therapy after tumor necrosis factor and interleukin-1 blockade
    Kurt Redlich
    University of Vienna, Vienna, Austria
    Arthritis Rheum 48:3308-19. 2003
  32. ncbi request reprint Characterization of autoreactive T cells to the autoantigens heterogeneous nuclear ribonucleoprotein A2 (RA33) and filaggrin in patients with rheumatoid arthritis
    Ruth Fritsch
    Division of Rheumatology, Department of Internal Medicine III, University of Vienna, Vienna, Austria
    J Immunol 169:1068-76. 2002
    ..Taken together, the presence of autoreactive Th1-like cells in RA patients in conjunction with synovial overexpression of A2/RA33 may indicate potential involvement of this autoantigen in the pathogenesis of RA...
  33. pmc Autoantibodies in rheumatoid arthritis and their clinical significance
    Günter Steiner
    Vienna General Hospital, University of Vienna, and Ludwig Boltzmann Institute for Rheumatology, Vienna, Austria
    Arthritis Res 4:S1-5. 2002
    ..These autoantibodies are reviewed and the potential role of the autoantibodies in the pathogenesis of RA is briefly discussed...